Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CHCL.B |
---|---|---|
03:59 ET | 0 | 22.7 |
US Equity | 72.2% |
---|---|
Int'l Equity | 27.7% |
Cash | 0.1% |
CDN Equity | 0 |
Fixed Income | 0 |
Other | 0 |
Healthcare | 99.2% |
---|---|
Consumer Defensive | 0.4% |
Industrials | 0.3% |
Technology | 0.1% |
Basic Mat. | 0 |
Communication Services | 0 |
Consumer Cyclical | 0 |
Energy | 0 |
Financial Serv.s | 0 |
Real Estate | 0 |
Utilities | 0 |
United States | 72.3% |
---|---|
Asia/Oceania | 6.0% |
Europe | 4.2% |
Africa | 0 |
Latin America | 0 |
Canada | 0 |
Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
---|---|---|---|---|
Eli Lilly and Co | Long | 8.7% | -6.96% | $21.8M |
UnitedHealth Group Inc | Long | 5.9% | -6.96% | $14.8M |
Novo Nordisk A/S Class B | Long | 5.4% | -6.96% | $13.6M |
Johnson & Johnson | Long | 4.6% | -6.96% | $11.5M |
Merck & Co Inc | Long | 4.3% | -6.96% | $10.8M |
AbbVie Inc | Long | 3.8% | -6.96% | $9.5M |
AstraZeneca PLC | Long | 3.0% | -6.96% | $7.5M |
Thermo Fisher Scientific Inc | Long | 2.9% | -6.96% | $7.2M |
Novartis AG Registered Shares | Long | 2.6% | -6.96% | $6.4M |
Abbott Laboratories | Long | 2.4% | -6.96% | $6.1M |
Time Horizon | Star Rating |
---|---|
Overall Rating | Not Rated |
3 Year Rating | Not Rated |
5 Year Rating | Not Rated |
10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
---|---|
Category | Sector Equity |
Sponsor | CI Global Asset Management |
Inception | August 12, 2021 |
CHCL seeks to replicate, to the extent reasonably possible, the performance of a global healthcare index, net of expenses. Currently, CHCL seeks to replicate the performance of the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR) (the “Indexâ€). The Index intends to track the performance of the largest 150 companies from the global healthcare industry.
Total Net Assets | $250.9M |
---|---|
Shares Out. | 11.4M |
Net Asset Value (NAV) | $22.67 |
Prem/Discount to NAV | -0.17% |
P/E Ratio | 30.6 |
Dividend Yield | 1.06% |
Dividend per Share | 0.24 CAD |
Ex-Dividend Date | 03/21/2024 |
Dividend Payment Date | 03/28/2024 |
Beta | --- |
Morningstar Investment Style | Sector Equity |
Equity Style | Large Cap Blend |
Credit Quality / Duration | --- |
Actual Management Fee | 0.35% |
---|---|
Actual Mgmt. Expense Ratio (MER) | 0.38% |